<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736866</url>
  </required_header>
  <id_info>
    <org_study_id>IEP- HCor 001/08</org_study_id>
    <nct_id>NCT00736866</nct_id>
  </id_info>
  <brief_title>The Acetylcysteine for Contrast-Induced Nephropathy Trial</brief_title>
  <acronym>ACT</acronym>
  <official_title>A Pragmatic Randomized Clinical Trial Evaluating the Effect of Acetylcysteine for Contrast-induced Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medley Pharmaceutical Industry SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of acetylcysteine compared to placebo
      for the contrast-induced nephropathy prevention, between 48 and 96 hours after procedures
      that use contrast.

      Contrast-induced nephropathy is defined as an increase of 25% in serum creatinine before the
      procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast-induced nephropathy incidence</measure>
    <time_frame>between 48 and 96 hours after angiographic procedures</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined outcome of total mortality, dialysis indication or basal serum creatinine duplication</measure>
    <time_frame>within 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined outcome of total mortality or dialysis indication</measure>
    <time_frame>within 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The individual components of the combined outcome</measure>
    <time_frame>within 30 dias</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Acute Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcysteine</intervention_name>
    <description>Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.</description>
    <arm_group_label>Acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At least one of the following criteria:

          -  Aged more than 70 years-old

          -  Chronic renal failure (defined as serum creatinine higher than 1.5mg/dL within the
             last 3 months)

          -  Diabetes mellitus

          -  Congestive heart failure or ventricular disfunction (left ventricular ejection
             fraction less than 0.45)

          -  Shock or intra-aortic balloon pump use

          -  Urgency or emergency procedures

        Exclusion Criteria:

          -  Pregnant women, breastfeeding or aged below 45 years-old and with no efficacious
             contraceptive methods.

          -  Patients in dialysis

          -  Previous inclusion in this trial

          -  Patient refusal to informed consent

          -  Pacientes com Infarto Agudo do Miocárdio com supradesnivelamento do segmento S-T nos
             quais não seja possível administrar o protocolo de hidratação pré e pós-procedimento.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Sousa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital do Coração</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04004030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <last_update_submitted>July 8, 2010</last_update_submitted>
  <last_update_submitted_qc>July 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Otavio Berwanger</name_title>
    <organization>Hospital do Coracao</organization>
  </responsible_party>
  <keyword>acetylcysteine</keyword>
  <keyword>contrast-induced nephropathy</keyword>
  <keyword>angiography</keyword>
  <keyword>angioplasty with or without Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

